Natera, Inc.

Equities

NTRA

US6323071042

Market Closed - Nasdaq Other stock markets 05:59:21 19/06/25 am AEST			5-day change	1st Jan Change
171.01 ^USD	+2.07%		+2.55%	+8.03%

10/06	Natera, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 02:00 PM
05/06	Sector Update: Health Care Stocks Advance Late Afternoon	MT

Natera, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 02:00 PM

Published on 10/06/2025 at 20:20, updated on 10/06/2025 at 20:35

Presenter Speech
Matt Sykes (Analysts)

Welcome, everybody. Good afternoon. I'm Matt Sykes, the Life Science Tools and Diagnostics Analyst at Goldman Sachs, and I have the pleasure of welcoming Mike

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Natera, Inc.

Natera, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 02:00 PM	10/06
Sector Update: Health Care Stocks Advance Late Afternoon	05/06	MT
Sector Update: Health Care Stocks Advance in Afternoon Trading	05/06	MT
Sector Update: Health Care	05/06	MT
Natera, Inc. Announces Medicare Coverage for Signatera Genome	04/06	CI
Natera Says Signatera Cancer Test Approved for Medicare Coverage	04/06	MT
Natera Inc - Signatera Assay Now Covered By Medicare	04/06	RE
Natera, Inc. Announces Results from A Large-Scale Pan-Cancer Study of Its Signatera Genome Assay	03/06	CI
Natera, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 10:30 AM	23/05
Natera Q1 Net Loss Narrows, Revenue Rises; Increases Full Year Revenue Outlook	09/05	MT
Natera, Inc., Q1 2025 Earnings Call, May 08, 2025	09/05
Earnings Flash (NTRA) NATERA INC. Reports Q1 Revenue $501.8M, vs. FactSet Est of $446.2M	09/05	MT
Natera, Inc. Provides Earnings Guidance for the Year 2025	09/05	CI
Natera, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	09/05	CI
Natera, Inc. Announces to Present Multiple Datasets in Breast Cancer Together with its Collaborators at 2025 ESMO Breast Cancer Annual Congress in Munich, Germany	09/05	CI
Natera, Inc. Announces the American Journal of Transplantation Publishes New Study Evaluating the Performance of Prospera Heart with Dqs to Detect Allograft Rejection	07/05	CI
Natera, Inc. Announces Results of Study Led by Stanford University School of Medicine for the Evaluation of Signatera	05/05	CI
Natera, Inc. Announces the Results of Its Define-HT Clinical Trial in Heart Transplantation	30/04	CI
Natera Announces Broad Clinical Launch of Ultra-S sensitive Signatera Genome MRD Test	24/04	CI
Natera, Inc. to Present Data from 8 Studies at 2025 AACR Annual Meeting	23/04	CI
RBC Initiates Natera at Outperform With $251 Price Target	13/03	MT
Natera, Inc. Appoints Monica Bertagnolli as A Member of the Board	13/03	CI
Natera, Inc. Presents at Leerink?s Global Healthcare Conference 2025, Mar-11-2025 10:40 AM	12/03
Natera, Inc. Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer	10/03	CI
Natera Set to Continue Upside Surprises During 2025, Beyond, Morgan Stanley Says	06/03	MT